Camptosar (irinotecan hydrochloride)
July 2, 2002
Audience: Oncologists and others caring for patients with metastatic colorectal cancer
The prescribing information in the BOXED WARNING, WARNINGS, and PRECAUTIONS sections were revised to identify patients at higher risk of severe toxicity, to clarify dose modification guidelines, and to augment information about management of treatment-related toxicities, including severe and occasionally life-threatening diarrhea.More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.